Errant epitopes from arginine methylated SARS-CoV-2 proteins predisposing to autoimmune diseases.

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:0 publications

Grant number: 177696

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2021
    2022
  • Known Financial Commitments (USD)

    $246,781.5
  • Funder

    Canadian Institutes of Health Research (CIHR)
  • Principal Investigator

    Stéphane Richard
  • Research Location

    Canada
  • Lead Research Institution

    Lady Davis Institute for Medical Research
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Drugs that can inhibit SARS-CoV-2 replication are urgently needed besides vaccines. The drugs can target the variants while vaccines provide limited immunity against only 1 protein, namely Spike. Our data show that viral proteins are modified post-translationally on arginine (methyl arginines) by protein arginine methyltransferases. This modification is necessary for the virus to suppress the anti-viral response and allow viral replication. We have shown that the N protein is arginine methylated and this is necessary for its function. Actually it is known that we develop antibodies against N protein, as it is very immunogenic. In addition, there are mutations in a key arginine residue in B.1.17 variant. In this proposal, we aim to understand how the methylated viral proteins are recognized by the immune system and if we will develop in the future autoimmune diseases because of this.